User:37and7/sandboxerc

Source: Wikipedia, the free encyclopedia.
Epitopoietic Research Corporation
Industry
EU))
Websitewww.erc-immunotherapy.com

Epitopoietic Research Corporation (ERC) is a Belgian Pharmaceutical company developing ERC1671 (brandnames: Gliovac, Sitoiganap (

brain cancer. In 2019, ERC became the first pharmaceutical company to provide treatment under the US Federal Right-to-try law.[1][2][3][4][5][6]

History:

The genesis of ERC1671 occurred when Apostolos Stathopoulos was a

tumor hit his eye. At first, Stathopoulos panicked, but then he realized his body’s immune system would destroy the cancer cells.[7]

2006:

Stathopoulos conducts a proof-of-concept study on rats. The study finds that the combination of Syngeneic and allogeneic glioma cells injected into rats with growing tumors reduce the size and even eradicate them of the existing tumors and prevented the formation of new tumors. Stathopoulos patents the technique and founds ERC to develop the treatment for humans. [8][9][10]

2009:

ERC obtains Advanced Medical Therapy Product status for Gliovac/ERC1671 from the European Medicines Agency. It creates a tissue bank for proliferative tumors and a Good Manufacturing Practice-compliant production facility in Schaijk, Netherlands.[11][12]

2011:

Gliovac obtains

FDA. Glioblastoma multiforme is the most common and deadly brain tumor in adults, but only affects 10,000-17,000 people in the US. By definition, an orphan disease affects under 200,000 people in the USA.[13]

Glioblastoma on an MRI

2012:

First patients are treated with Gliovac/ERC1671 under a doctrine of

compassionate use. In September, the first patient reached total remission.[14][15]

2013:

Phase II trials of Gliovac/ERC1671 begins in partnership with the University of California, Irvine.[16]

2018:

Interim phase II trial results show that patients treated with Gliovac/ERC1671 and the commonly prescribed anti-cancer drug bevacizumab(Atavan) survived almost five months longer on average than those treated with bevacizumab alone.[17]

2019

At the request of a patient, Gliovac/ERC1671 is the first medication prescribed under US Federal

Trump Administration. Despite being prescribed under Federal law, the treatment follows the protocols of California’s state Right-To-Try laws. ERC makes Gliovac available at free or reduced cost for Right-To-Try patients.[18][19]

2020

ERC submits a

Covid-19 vaccine called COVIDVAC based on Gliovac technology.[21][22]

Leadership:

Apostolos Stathopoulos (Co-Founder, CEO) is an

Abigail Alliance.[23][24][25]

Thomas Chen (Co-Founder, CMO) is an MD/PhD Neurosurgeon and Professor at the University of Southern California. He is one of the few fellowship trained spinal surgeons focused on spine cancer.[26]

Virgil Schijns, PhD (Chief Scientific Officer) is the Registered Qualified Person for Gliovac/ERC1671 in the EU.[27][28]

Joe Elliott is the head of ERC-USA, ERC's US Subsidiary.[29]

Vince Dell Co-Founded ERC-USA and serves as CFO.[30]

Products:

Sitoiganap (EU)/Gliovac/ERC1671 is an immunotherapy vaccine that trains the body’s immune system to attack a Glioblastoma (brain tumor) using cells taken from the patient’s own tumor, along with tumor cells from three other donors. Unlike most vaccines, it is only given to patients who have already developed the disease, rather than prophylactically. By receiving tumor cells from different people, the patient’s immune system is exposed to several different tumor-associated antigens (TAA), or proteins, minimizing the chance that tumor cells might escape from the body’s defenses. It also is believed this approach will trigger a stronger

UK’s National Health Service:

The key principle underlying this particular vaccination approach is the use of a broad set of tumour antigens, derived from freshly resected whole tumour tissue – not only from the patient under treatment, but expanded to include the same from three independent GBM tissue donors. This multivalent array of autologous and allogeneic antigens is expected to reduce the chance of immune escape, which can emerge from antigenic loss or active major histocompatibility complex (MHC) downregulation and is more likely to occur when using a single- or limited-antigen targeted immunotherapy. The future promise of this treatment might also rest in the ability to combine it with bevacizumab, and potentially with immune checkpoint inhibitors – an option that will allow more powerful immune activation in the periphery as well as more aggressive local tumour immunological targeting and destruction.[33][34]

In April 2020, ERC began development on COVIDVAC, a vaccine for

Covid-19 based on ERC1671’s underlying technology.[35][36]

References

  1. ^ "Epitopoietic Research Corporation". ERC. 2020-04-09. Retrieved 2020-07-02.
  2. ^ "k8fT0MoqyMcug16mplqDtQ2". S&P Global Market Intelligence. 2019-11-26. Retrieved 2020-07-02.
  3. ^ ERC-USA (2019-11-19). "ERC-USA Sponsors Ancillary Meeting to Discuss Outcomes from Its Clinical Trial and Right To Try Patient Experience of ERC1671 in Recurrent Glioblastoma". GlobeNewswire News Room. Retrieved 2020-07-02.
  4. PMID 25785641
    . Retrieved 2020-07-02.
  5. ^ "ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP". Yahoo Finance. 2018-08-26. Retrieved 2020-07-02.
  6. ^ Michelle Fay Cortez (2019-01-10). "Brain Cancer Patient Is First to Get Untested Treatment Under Trump-Backed Law". www.bloomberg.com.
  7. ^ "Epitopoietic Research Corporation - Le cancer vaincu par l'intérieur". Waw magazine (in French). 2017-07-04. Retrieved 2020-07-02.
  8. PMID 18336964
    .
  9. ^ [1], Stathopoulos, Apostolos, "Tumour Vaccine Comprising Allogeneic or Xenogeneic Tumour Cells", issued 2007-08-02 
  10. ^ www.erc.eu. "ERC - Epitopoietic Research Corporation". erc.konnu.be. Retrieved 2020-07-02.
  11. ^ "ERC: Epitopoietic Research Corporation Netherlands". Rhumbline Consultancy (in Dutch). 2015-04-12. Retrieved 2020-07-02.
  12. PMID 30150597.{{cite journal}}: CS1 maint: unflagged free DOI (link
    )
  13. ^ Lassen, Ulrik; Mau-Sørensen, Morten; Poulsen, Hans Skovgaard (2014-11-14). "Orphan drugs in glioblastoma multiforme: a review". Orphan Drugs: Research and Reviews. Retrieved 2020-07-02.
  14. ^ "Gliovac (ERC1671)". Immuno-Oncology News. Retrieved 2020-07-02.
  15. PMID 25865468
    .
  16. ^ "ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-07-02.
  17. PMID 30157683.{{cite journal}}: CS1 maint: PMC format (link
    )
  18. ^ "Right to Try Program Offers Hope to Brain Cancer Patients". Goldwater Institute. Retrieved 2020-07-02.
  19. ^ "Glioblastoma patient is first to receive treatment under Right to Try. Our question is Why? – The Cancer Letter". The Cancer Letter – The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology. 2019-02-01. Retrieved 2020-07-02.
  20. ^ "ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP". finance.yahoo.com. Retrieved 2020-07-14.
  21. ^ "ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme". Smart Patients.{{cite web}}: CS1 maint: url-status (link)
  22. ^ Martin, Ulrich (2020-04-10). "The Biologics News and Reports Portal". pipelinereview. Retrieved 2020-07-02.
  23. ^ "The Abigail Alliance for Better Access to Developmental Drugs: Dr. Stathopoulos: Humanitarian of the Year for 2019". webcache.googleusercontent.com. Retrieved 2020-07-02.
  24. ^ "Stathopoulos Apostolos". Henry Dunant. Retrieved 2020-07-02.
  25. ^ "ImmunoNeuroSurgery". ImmunoNeuroSurgery. 2006-03-18. Retrieved 2020-07-02.
  26. ^ "ERC Immunotherapy". tracxn.com. Retrieved 2020-07-02.
  27. ^ Home">"Prof.dr. V.E.J.C. (Virgil) Schijns (https://www.narcis.nl)". NARCIS > Home. Retrieved 2020-07-02.
  28. ^ "Virgil Schijns". WUR. 2012-11-05. Retrieved 2020-07-02.
  29. ^ Michelle Fay Cortez (2019-01-10). "Brain Cancer Patient is First to Get Untested Treatment Under Trump-Backed Law". www.bloomberg.com. Retrieved 2020-07-14.
  30. ^ "EPITOPOIETIC RESEARCH CORPORATION · 18247 Bathurst St, Northridge, CA 91326-2024". opengovus.com. Retrieved 2020-07-14.
  31. ^ PhD, Ines Martins. "Gliovac (ERC1671) - Immuno-Oncology News". Retrieved 2020-07-02.
  32. PMID 25865468
    .
  33. PMID 25785641
    .
  34. ^ Innovation Observatory. "ERC1671 (Gliovac) for recurrent grade IV glioma" (PDF). Health Technology Briefing - March 2019. Retrieved 07/02/2020. {{cite news}}: Check date values in: |access-date= (help)CS1 maint: url-status (link)
  35. ^ ERC-USA (2020-04-09). "ERC Launches Development Program for Novel Cell-Based Therapeutic and Prophylactic SARS-CoV-2 Vaccine". GlobeNewswire News Room. Retrieved 2020-07-02.
  36. ^ Martin, Ulrich. "The Biologics News and Reports Portal". pipelinereview. Retrieved 2020-07-02.
This page will be placed in the following categories if it is moved to the
article namespace.
Categories:
  • Oncology
  • Businesses in Belgium
  • Small and Medium-Sized Enterprises
    • Retrieved from "https://en.wikipedia.org/w/index.php?title=User:37and7/sandboxerc&oldid=967706119"